A Women-Focused PrEP Intervention
Just4Us
Developing a Women-Focused PrEP Intervention for HIV Prevention
1 other identifier
interventional
83
1 country
1
Brief Summary
Many women at high risk for acquiring HIV infection are not aware of preexposure prophylaxis (PrEP), an efficacious, self-administered, woman-controlled, HIV prevention product. The objective of this study is to evaluate the feasibility and acceptability of a theory-based intervention to promote PrEP uptake and adherence in a pilot trial among 80 women. The study will also measure intention to use PrEP and actual initiation of PrEP use. The investigators hypothesize that the intervention will be acceptable and feasible and that the intervention group will report higher levels of PrEP uptake, intention to use and adhere to PrEP, and other variables regarding PrEP uptake, comparing baseline, post-intervention and 3 month follow-up assessments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Nov 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2018
CompletedFirst Posted
Study publicly available on registry
October 9, 2018
CompletedStudy Start
First participant enrolled
November 3, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 10, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 10, 2019
CompletedNovember 13, 2020
November 1, 2020
11 months
September 29, 2018
November 12, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Intervention Fidelity
Evaluation of fidelity behavior for each module by site coordinator after listening to audio recordings of intervention sessions using a rating form with 90% evaluation items must be 4s or 5s on a 5-point Likert scale.
baseline session
Participant Acceptability of intervention
At least 80% of participants report moderate or higher levels of acceptability: based on participants' indicating favorable responses indicated by 4s and 5s on a 5 point Likert scale on the Brief Satisfaction Questionnaire
baseline and 3 months
Secondary Outcomes (1)
PrEP uptake behavior
3 months
Study Arms (2)
Education + Activities
EXPERIMENTAL12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
Information
ACTIVE COMPARATORPrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
Interventions
Format:Video; discussion; information handouts; facilitated referral
Eligibility Criteria
You may qualify if:
- female at birth and identify as female
- aged 18-55;
- report unprotected vaginal or anal sex with a male partner OR any injection drug use in the past 6 months;
- live or have sex in a high risk area or are recruited into the study by someone who lives or has sex in a high risk area;
- understand and read English;
- not known to be HIV-infected;
- are willing to consider a daily pill with low rates of mild side effects to prevent HIV;
- have access to a mobile phone.
- report at least one of the following as 'yes' or 'do not know': current male partner who injects drugs or has sex with men; current male partner who is HIV infected; current male partner who was incarcerated in the last 6 months OR report at least one of the following as 'yes': shared injection equipment in last 6 months; in methadone, buprenorphine or suboxone treatment program in past 6 months; exchange sex for money, drugs, other goods in last 6 months; powder cocaine, crack use, methamphetamines, or ecstasy \>1x/week in last 6 months; Chlamydia, syphilis, gonorrhea diagnosed or newly diagnosed genital herpes in last 6 months; alcohol abuse in last 6 months (defined as a score of 2 or higher on the CAGE36); has 3 or more male partners.
You may not qualify if:
- currently using PrEP
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pennsylvanialead
- New York Blood Centercollaborator
Study Sites (1)
Anne Teitelman
Philadelphia, Pennsylvania, 19104, United States
Related Publications (2)
Teitelman AM, Tieu HV, Chittamuru D, Shaw PA, Nandi V, Davis A, Lipsky RK, Darlington CK, Fiore D, Koblin BA. A Randomized Controlled Pilot Study of Just4Us, a Counseling and Navigation Intervention to Promote Oral HIV Prophylaxis Uptake Among PrEP-Eligible Cisgender Women. AIDS Behav. 2023 Sep;27(9):2944-2958. doi: 10.1007/s10461-023-04017-z. Epub 2023 Mar 4.
PMID: 36869921DERIVEDTeitelman AM, Koblin BA, Brawner BM, Davis A, Darlington C, Lipsky RK, Iwu E, Bond KT, Westover J, Fiore D, Tieu HV. Just4Us: Development of a Counselor-Navigator and Text Message Intervention to Promote PrEP Uptake Among Cisgender Women at Elevated Risk for HIV. J Assoc Nurses AIDS Care. 2021 Mar-Apr 01;32(2):188-204. doi: 10.1097/JNC.0000000000000233.
PMID: 33427767DERIVED
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
September 29, 2018
First Posted
October 9, 2018
Study Start
November 3, 2018
Primary Completion
October 10, 2019
Study Completion
November 10, 2019
Last Updated
November 13, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share
We are happy to make our research findings readily available for research purposes to qualified individuals within the scientific community through individual requests directed to the Co-Principal Investigators and to share all published findings with the NIH. To protect confidentiality, qualitative data will be release in summary form. Findings from the study will be transmitted both to the scientific community through presentations at conferences and via journal articles and to interested community members through presentations. At each presentation and on each publication, contact information for additional information will be provided.